APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Central Nervous System

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Central Nervous System Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs for Central Nervous System Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Central Nervous System Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Drugs for Central Nervous System Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Central Nervous System Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Central Nervous System Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Drugs for Central Nervous System market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Central Nervous System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Central Nervous System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Central Nervous System is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Central Nervous System market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Central Nervous System market include Takeda, Teva, Johnson & Johnson, Novartis, Novartis, Merck, Pfizer, Biogen and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Central Nervous System market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Central Nervous System and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Central Nervous System sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Central Nervous System market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Central Nervous System Segment by Company

Takeda

Teva

Johnson & Johnson

Novartis

Novartis

Merck

Pfizer

Biogen

AstraZeneca

Otsuka

EliLilly

Drugs for Central Nervous System Segment by Type

OTC

Rx Drugs

Drugs for Central Nervous System Segment by Application

Hospital

Retail Pharmacy

Drugs for Central Nervous System Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Central Nervous System status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Central Nervous System market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Central Nervous System significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Central Nervous System competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Central Nervous System market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Central Nervous System and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Central Nervous System.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Central Nervous System market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Central Nervous System industry.

Chapter 3: Detailed analysis of Drugs for Central Nervous System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Central Nervous System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Central Nervous System in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Central Nervous System Industry Trends Table 2. Drugs for Central Nervous System Industry Drivers Table 3. Drugs for Central Nervous System Industry Opportunities and Challenges Table 4. Drugs for Central Nervous System Industry Restraints Table 5. Global Drugs for Central Nervous System Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Central Nervous System Revenue Share by Company (2021-2026) Table 7. Global Drugs for Central Nervous System Sales Volume by Company (k units) & (2021-2026) Table 8. Global Drugs for Central Nervous System Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Central Nervous System Average Price (US$/unit) of Company (2021-2026) Table 10. Global Drugs for Central Nervous System Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Central Nervous System Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Central Nervous System Company, Product Type & Application Table 13. Global Drugs for Central Nervous System Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Central Nervous System by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of OTC Table 18. Significant Companies of Rx Drugs Table 19. Global Drugs for Central Nervous System Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Drugs for Central Nervous System Sales Volume by Type (2021-2026) & (k units) Table 21. Global Drugs for Central Nervous System Sales Volume by Type (2027-2032) & (k units) Table 22. Global Drugs for Central Nervous System Sales Volume Share by Type (2021-2026) Table 23. Global Drugs for Central Nervous System Sales Volume Share by Type (2027-2032) Table 24. Global Drugs for Central Nervous System Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for Central Nervous System Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Drugs for Central Nervous System Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Drugs for Central Nervous System Sales Value Share by Type (2021-2026) Table 28. Global Drugs for Central Nervous System Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Retail Pharmacy Table 31. Global Drugs for Central Nervous System Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Drugs for Central Nervous System Sales Volume by Application (2021-2026) & (k units) Table 33. Global Drugs for Central Nervous System Sales Volume by Application (2027-2032) & (k units) Table 34. Global Drugs for Central Nervous System Sales Volume Share by Application (2021-2026) Table 35. Global Drugs for Central Nervous System Sales Volume Share by Application (2027-2032) Table 36. Global Drugs for Central Nervous System Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Drugs for Central Nervous System Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Drugs for Central Nervous System Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Drugs for Central Nervous System Sales Value Share by Application (2021-2026) Table 40. Global Drugs for Central Nervous System Sales Value Share by Application (2027-2032) Table 41. Global Drugs for Central Nervous System Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Drugs for Central Nervous System Sales by Region (2021-2026) & (k units) Table 43. Global Drugs for Central Nervous System Sales Market Share by Region (2021-2026) Table 44. Global Drugs for Central Nervous System Sales by Region (2027-2032) & (k units) Table 45. Global Drugs for Central Nervous System Sales Market Share by Region (2027-2032) Table 46. Global Drugs for Central Nervous System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Drugs for Central Nervous System Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Drugs for Central Nervous System Sales Value Share by Region (2021-2026) Table 49. Global Drugs for Central Nervous System Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Drugs for Central Nervous System Sales Value Share by Region (2027-2032) Table 51. Global Drugs for Central Nervous System Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Drugs for Central Nervous System Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Drugs for Central Nervous System Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Drugs for Central Nervous System Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Drugs for Central Nervous System Sales by Country (2021-2026) & (k units) Table 56. Global Drugs for Central Nervous System Sales Market Share by Country (2021-2026) Table 57. Global Drugs for Central Nervous System Sales by Country (2027-2032) & (k units) Table 58. Global Drugs for Central Nervous System Sales Market Share by Country (2027-2032) Table 59. Global Drugs for Central Nervous System Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Drugs for Central Nervous System Sales Value Market Share by Country (2021-2026) Table 61. Global Drugs for Central Nervous System Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Drugs for Central Nervous System Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Takeda Drugs for Central Nervous System Product Portfolio Table 67. Takeda Recent Development Table 68. Teva Company Information Table 69. Teva Business Overview Table 70. Teva Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Teva Drugs for Central Nervous System Product Portfolio Table 72. Teva Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Drugs for Central Nervous System Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis Drugs for Central Nervous System Product Portfolio Table 82. Novartis Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Novartis Drugs for Central Nervous System Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Merck Drugs for Central Nervous System Product Portfolio Table 92. Merck Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Pfizer Drugs for Central Nervous System Product Portfolio Table 97. Pfizer Recent Development Table 98. Biogen Company Information Table 99. Biogen Business Overview Table 100. Biogen Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Biogen Drugs for Central Nervous System Product Portfolio Table 102. Biogen Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. AstraZeneca Drugs for Central Nervous System Product Portfolio Table 107. AstraZeneca Recent Development Table 108. Otsuka Company Information Table 109. Otsuka Business Overview Table 110. Otsuka Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Otsuka Drugs for Central Nervous System Product Portfolio Table 112. Otsuka Recent Development Table 113. EliLilly Company Information Table 114. EliLilly Business Overview Table 115. EliLilly Drugs for Central Nervous System Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. EliLilly Drugs for Central Nervous System Product Portfolio Table 117. EliLilly Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Drugs for Central Nervous System Distributors List Table 121. Drugs for Central Nervous System Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Drugs for Central Nervous System Product Image Figure 2. Global Drugs for Central Nervous System Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Central Nervous System Sales (2021-2032) & (k units) Figure 5. Global Drugs for Central Nervous System Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Drugs for Central Nervous System Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. OTC Image Figure 10. Rx Drugs Image Figure 11. Global Drugs for Central Nervous System Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Drugs for Central Nervous System Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Central Nervous System Sales Volume Share by Type (2021-2032) Figure 14. Global Drugs for Central Nervous System Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Drugs for Central Nervous System Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Central Nervous System Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Retail Pharmacy Image Figure 19. Global Drugs for Central Nervous System Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Drugs for Central Nervous System Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Drugs for Central Nervous System Sales Volume Share by Application (2021-2032) Figure 22. Global Drugs for Central Nervous System Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Drugs for Central Nervous System Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for Central Nervous System Sales Value Share by Application (2021-2032) Figure 25. Global Drugs for Central Nervous System Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Drugs for Central Nervous System Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Drugs for Central Nervous System Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Drugs for Central Nervous System Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 30. North America Drugs for Central Nervous System Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Drugs for Central Nervous System Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Drugs for Central Nervous System Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 36. South America Drugs for Central Nervous System Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Drugs for Central Nervous System Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Drugs for Central Nervous System Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Drugs for Central Nervous System Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Drugs for Central Nervous System Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Drugs for Central Nervous System Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx Drugs
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Takeda
  • Teva
  • Johnson & Johnson
  • Novartis
  • Novartis
  • Merck
  • Pfizer
  • Biogen
  • AstraZeneca
  • Otsuka
  • EliLilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Central Nervous System Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Central Nervous System Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Central Nervous System Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Central Nervous System Market Dynamics
  1. 2.1 Drugs for Central Nervous System Industry Trends
  2. 2.2 Drugs for Central Nervous System Industry Drivers
  3. 2.3 Drugs for Central Nervous System Industry Opportunities and Challenges
  4. 2.4 Drugs for Central Nervous System Industry Restraints
3 Drugs for Central Nervous System Market by Company
  1. 3.1 Global Drugs for Central Nervous System Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Central Nervous System Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Central Nervous System Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Central Nervous System Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Central Nervous System Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Central Nervous System Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Central Nervous System Company Product Type and Application
  8. 3.8 Global Drugs for Central Nervous System Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Central Nervous System Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Central Nervous System Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Central Nervous System Market by Type
  1. 4.1 Drugs for Central Nervous System Type Introduction
  2. 4.1.1 OTC
  3. 4.1.2 Rx Drugs
  4. 4.2 Global Drugs for Central Nervous System Sales Volume by Type
  5. 4.2.1 Global Drugs for Central Nervous System Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for Central Nervous System Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Drugs for Central Nervous System Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Drugs for Central Nervous System Sales Value by Type
  9. 4.3.1 Global Drugs for Central Nervous System Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs for Central Nervous System Sales Value by Type (2021-2032)
  11. 4.3.3 Global Drugs for Central Nervous System Sales Value Share by Type (2021-2032)
5 Drugs for Central Nervous System Market by Application
  1. 5.1 Drugs for Central Nervous System Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Drugs for Central Nervous System Sales Volume by Application
  5. 5.2.1 Global Drugs for Central Nervous System Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drugs for Central Nervous System Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Drugs for Central Nervous System Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Drugs for Central Nervous System Sales Value by Application
  9. 5.3.1 Global Drugs for Central Nervous System Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Drugs for Central Nervous System Sales Value by Application (2021-2032)
  11. 5.3.3 Global Drugs for Central Nervous System Sales Value Share by Application (2021-2032)
6 Drugs for Central Nervous System Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Central Nervous System Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Central Nervous System Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Central Nervous System Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Central Nervous System Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Central Nervous System Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Central Nervous System Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Central Nervous System Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Central Nervous System Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Central Nervous System Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Central Nervous System Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Central Nervous System Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Central Nervous System Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Central Nervous System Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Central Nervous System Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Central Nervous System Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Central Nervous System Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Central Nervous System Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Central Nervous System Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Central Nervous System Sales Value Share by Country, 2025 VS 2032
7 Drugs for Central Nervous System Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Central Nervous System Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Central Nervous System Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Central Nervous System Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Central Nervous System Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Central Nervous System Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Central Nervous System Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Central Nervous System Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Central Nervous System Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Central Nervous System Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Central Nervous System Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Central Nervous System Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Drugs for Central Nervous System Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Drugs for Central Nervous System Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Drugs for Central Nervous System Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Drugs for Central Nervous System Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Drugs for Central Nervous System Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Drugs for Central Nervous System Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Drugs for Central Nervous System Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Drugs for Central Nervous System Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Drugs for Central Nervous System Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Otsuka
  56. 8.10.1 Otsuka Company Information
  57. 8.10.2 Otsuka Business Overview
  58. 8.10.3 Otsuka Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Otsuka Drugs for Central Nervous System Product Portfolio
  60. 8.10.5 Otsuka Recent Developments
  61. 8.11 EliLilly
  62. 8.11.1 EliLilly Company Information
  63. 8.11.2 EliLilly Business Overview
  64. 8.11.3 EliLilly Drugs for Central Nervous System Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 EliLilly Drugs for Central Nervous System Product Portfolio
  66. 8.11.5 EliLilly Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Central Nervous System Value Chain Analysis
  2. 9.1.1 Drugs for Central Nervous System Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Central Nervous System Sales Mode & Process
  6. 9.2 Drugs for Central Nervous System Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Central Nervous System Distributors
  9. 9.2.3 Drugs for Central Nervous System Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst